Skip to main content
Erschienen in: Cardiovascular Intervention and Therapeutics 1/2018

01.08.2017 | Review Article

Imaging assessment of bioresorbable vascular scaffolds

verfasst von: Yohei Sotomi, Pannipa Suwannasom, Erhan Tenekecioglu, Carlos Collet, Shimpei Nakatani, Takayuki Okamura, Takashi Muramatsu, Yuki Ishibashi, Hiroki Tateishi, Yosuke Miyazaki, Taku Asano, Yuki Katagiri, Constantin von zur Muehlen, Kengo Tanabe, Ken Kozuma, Yukio Ozaki, Patrick W. Serruys, Yoshinobu Onuma

Erschienen in: Cardiovascular Intervention and Therapeutics | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Vascular reparative therapy has become a reality with bioresorbable scaffolds (BRSs). To assess acute and long-term performance of the device, multimodality imaging would be essential. Radiopacity of metal hinders the imaging assessment, whereas radiolucent polymeric scaffolds allow for a precise imaging assessment with either invasive or non-invasive modality at baseline and at follow-up, which is one of the advantages of polymeric BRSs. Recent large trials evaluating clinical results of the first-generation BRS technology raised concerns about the safety and efficacy of these devices, namely, scaffold thrombosis. Intensive research with multimodality imaging in the field is being conducted to have in-depth understanding of the issues, which will facilitate the improvement of implantation techniques and the development of the next-generation BRSs. The current review focuses on the clinical application of the imaging modalities to assess the short- and long-term performance of the Absorb BVS.
Literatur
1.
Zurück zum Zitat Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J. 2012;33:16–25b.CrossRefPubMed Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J. 2012;33:16–25b.CrossRefPubMed
2.
Zurück zum Zitat Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, et al. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2014;7:1400–11.CrossRefPubMed Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, et al. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2014;7:1400–11.CrossRefPubMed
3.
Zurück zum Zitat Nakatani S, Ishibashi Y, Sotomi Y, Perkins L, Eggermont J, Grundeken MJ, et al. Bioresorption and vessel wall integration of a fully bioresorbable polymeric everolimus-eluting scaffold: optical coherence tomography, intravascular ultrasound, and histological study in a porcine model with 4-year follow-up. JACC Cardiovasc Interv. 2016;9:838–51.CrossRefPubMed Nakatani S, Ishibashi Y, Sotomi Y, Perkins L, Eggermont J, Grundeken MJ, et al. Bioresorption and vessel wall integration of a fully bioresorbable polymeric everolimus-eluting scaffold: optical coherence tomography, intravascular ultrasound, and histological study in a porcine model with 4-year follow-up. JACC Cardiovasc Interv. 2016;9:838–51.CrossRefPubMed
4.
Zurück zum Zitat Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.CrossRefPubMed Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.CrossRefPubMed
5.
Zurück zum Zitat Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479–91.CrossRefPubMed Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479–91.CrossRefPubMed
6.
Zurück zum Zitat Collet C, Asano T, Sotomi Y, Cavalcante R, Miyazaki Y, Zeng Y, et al. Early, late and very late incidence of bioresorbable scaffold thrombosis: a systematic review and meta-analysis of randomized clinical trials and observational studies. Minerva Cardioangiol. 2017;65:32–51.PubMed Collet C, Asano T, Sotomi Y, Cavalcante R, Miyazaki Y, Zeng Y, et al. Early, late and very late incidence of bioresorbable scaffold thrombosis: a systematic review and meta-analysis of randomized clinical trials and observational studies. Minerva Cardioangiol. 2017;65:32–51.PubMed
7.
Zurück zum Zitat Wykrzykowska JJ, Kraak RP, Hofma SH, et al. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med. 2017;376:2319–28.CrossRefPubMed Wykrzykowska JJ, Kraak RP, Hofma SH, et al. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med. 2017;376:2319–28.CrossRefPubMed
8.
Zurück zum Zitat Onuma Y, Sotomi Y, Shiomi H, Ozaki Y, Namiki A, Yasuda S, et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention. 2016;12:1090–101.CrossRefPubMed Onuma Y, Sotomi Y, Shiomi H, Ozaki Y, Namiki A, Yasuda S, et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention. 2016;12:1090–101.CrossRefPubMed
9.
Zurück zum Zitat Sotomi Y, Onuma Y, Collet C, Tenekecioglu E, Virmani R, Kleiman NS, et al. Bioresorbable scaffold: the emerging reality and future directions. Circ Res. 2017;120:1341–52.CrossRefPubMed Sotomi Y, Onuma Y, Collet C, Tenekecioglu E, Virmani R, Kleiman NS, et al. Bioresorbable scaffold: the emerging reality and future directions. Circ Res. 2017;120:1341–52.CrossRefPubMed
10.
Zurück zum Zitat Nakatani S, Onuma Y, Ishibashi Y, Eggermont J, Zhang YJ, Campos CM, et al. Temporal evolution of strut light intensity after implantation of bioresorbable polymeric intracoronary scaffolds in the ABSORB cohort B trial-an application of a new quantitative method based on optical coherence tomography. Circ J. 2014;78:1873–81.CrossRefPubMed Nakatani S, Onuma Y, Ishibashi Y, Eggermont J, Zhang YJ, Campos CM, et al. Temporal evolution of strut light intensity after implantation of bioresorbable polymeric intracoronary scaffolds in the ABSORB cohort B trial-an application of a new quantitative method based on optical coherence tomography. Circ J. 2014;78:1873–81.CrossRefPubMed
11.
Zurück zum Zitat Ishibashi Y, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, Garcia-Garcia HM, et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients From 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv. 2015;8:1715–26.CrossRefPubMed Ishibashi Y, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, Garcia-Garcia HM, et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients From 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc Interv. 2015;8:1715–26.CrossRefPubMed
12.
Zurück zum Zitat Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897–910.CrossRefPubMed Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897–910.CrossRefPubMed
13.
Zurück zum Zitat Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58:1578–88.CrossRefPubMed Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58:1578–88.CrossRefPubMed
14.
Zurück zum Zitat Okamura T, Onuma Y, Garcia-Garcia HM, van Geuns RJ, Wykrzykowska JJ, Schultz C, et al. First-in-man evaluation of intravascular optical frequency domain imaging (OFDI) of Terumo: a comparison with intravascular ultrasound and quantitative coronary angiography. EuroIntervention. 2011;6:1037–45.CrossRefPubMed Okamura T, Onuma Y, Garcia-Garcia HM, van Geuns RJ, Wykrzykowska JJ, Schultz C, et al. First-in-man evaluation of intravascular optical frequency domain imaging (OFDI) of Terumo: a comparison with intravascular ultrasound and quantitative coronary angiography. EuroIntervention. 2011;6:1037–45.CrossRefPubMed
15.
Zurück zum Zitat Tsuchida K, van der Giessen WJ, Patterson M, Tanimoto S, Garcia-Garcia HM, Regar E, et al. In vivo validation of a novel three-dimensional quantitative coronary angiography system (CardiOp-B): comparison with a conventional two-dimensional system (CAAS II) and with special reference to optical coherence tomography. EuroIntervention. 2007;3:100–8.PubMed Tsuchida K, van der Giessen WJ, Patterson M, Tanimoto S, Garcia-Garcia HM, Regar E, et al. In vivo validation of a novel three-dimensional quantitative coronary angiography system (CardiOp-B): comparison with a conventional two-dimensional system (CAAS II) and with special reference to optical coherence tomography. EuroIntervention. 2007;3:100–8.PubMed
16.
Zurück zum Zitat Sotomi Y, Onuma Y, Suwannasom P, Tateishi H, Tenekecioglu E, Zeng Y, et al. Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold? EuroIntervention. 2016;12:e998–1008.CrossRefPubMed Sotomi Y, Onuma Y, Suwannasom P, Tateishi H, Tenekecioglu E, Zeng Y, et al. Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold? EuroIntervention. 2016;12:e998–1008.CrossRefPubMed
18.
Zurück zum Zitat Sotomi Y, Onuma Y, Miyazaki Y, et al. Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus eluting bioresorbable polylactide scaffold in comparison with the cobalt chromium metallic stent? EuroIntervention. 2017. doi:10.4244/EIJ-D-17-00070. Sotomi Y, Onuma Y, Miyazaki Y, et al. Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus eluting bioresorbable polylactide scaffold in comparison with the cobalt chromium metallic stent? EuroIntervention. 2017. doi:10.​4244/​EIJ-D-17-00070.
19.
Zurück zum Zitat Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS), et al. A report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2001;37:1478–92.CrossRefPubMed Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS), et al. A report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2001;37:1478–92.CrossRefPubMed
20.
Zurück zum Zitat Mintz GS, Garcia-Garcia HM, Nicholls SJ, Weissman NJ, Bruining N, Crowe T, et al. Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention. 2011;6(1123–1130):1129. Mintz GS, Garcia-Garcia HM, Nicholls SJ, Weissman NJ, Bruining N, Crowe T, et al. Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention. 2011;6(1123–1130):1129.
21.
Zurück zum Zitat Steinvil A, Rogers T, Torguson R, Waksman R. Overview of the 2016 US food and drug administration circulatory system devices advisory panel meeting on the absorb bioresorbable vascular scaffold system. JACC Cardiovasc Interv. 2016;9:1757–64.CrossRefPubMed Steinvil A, Rogers T, Torguson R, Waksman R. Overview of the 2016 US food and drug administration circulatory system devices advisory panel meeting on the absorb bioresorbable vascular scaffold system. JACC Cardiovasc Interv. 2016;9:1757–64.CrossRefPubMed
22.
Zurück zum Zitat Sotomi Y, Suwannasom P, Tenekecioglu E, Tateishi H, Abdelghani M, Serruys PW, et al. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use. Expert Rev Cardiovasc Ther. 2015;13:1127–45.CrossRefPubMed Sotomi Y, Suwannasom P, Tenekecioglu E, Tateishi H, Abdelghani M, Serruys PW, et al. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use. Expert Rev Cardiovasc Ther. 2015;13:1127–45.CrossRefPubMed
23.
Zurück zum Zitat Brugaletta S, Gomez-Lara J, Diletti R, Farooq V, van Geuns RJ, de Bruyne B, et al. Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2012;79:219–28.CrossRefPubMed Brugaletta S, Gomez-Lara J, Diletti R, Farooq V, van Geuns RJ, de Bruyne B, et al. Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2012;79:219–28.CrossRefPubMed
24.
Zurück zum Zitat Suwannasom P, Sotomi Y, Ishibashi Y, Cavalcante R, Albuquerque FN, Macaya C, et al. The impact of post-procedural asymmetry, expansion, and eccentricity of bioresorbable everolimus-eluting scaffold and metallic everolimus-eluting stent on clinical outcomes in the ABSORB II trial. JACC Cardiovasc Interv. 2016;9:1231–42.CrossRefPubMed Suwannasom P, Sotomi Y, Ishibashi Y, Cavalcante R, Albuquerque FN, Macaya C, et al. The impact of post-procedural asymmetry, expansion, and eccentricity of bioresorbable everolimus-eluting scaffold and metallic everolimus-eluting stent on clinical outcomes in the ABSORB II trial. JACC Cardiovasc Interv. 2016;9:1231–42.CrossRefPubMed
25.
Zurück zum Zitat Gomez-Lara J, Brugaletta S, Diletti R, Gogas BD, Farooq V, Onuma Y, et al. Agreement and reproducibility of gray-scale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. Catheter Cardiovasc Interv. 2012;79:890–902.CrossRefPubMed Gomez-Lara J, Brugaletta S, Diletti R, Gogas BD, Farooq V, Onuma Y, et al. Agreement and reproducibility of gray-scale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. Catheter Cardiovasc Interv. 2012;79:890–902.CrossRefPubMed
26.
Zurück zum Zitat Brown AJ, McCormick LM, Hoole SP, West NE. Coregistered intravascular ultrasound and optical coherence tomography imaging during implantation of a bioresorbable vascular scaffold. JACC Cardiovasc Interv. 2013;6:e41–2.CrossRefPubMed Brown AJ, McCormick LM, Hoole SP, West NE. Coregistered intravascular ultrasound and optical coherence tomography imaging during implantation of a bioresorbable vascular scaffold. JACC Cardiovasc Interv. 2013;6:e41–2.CrossRefPubMed
27.
Zurück zum Zitat Chin CY, Maehara A, Fall K, Mintz GS, Ali ZA. Imaging comparisons of coregistered native and stented coronary segments by high-definition 60-MHz intravascular ultrasound and optical coherence tomography. JACC Cardiovasc Interv. 2016;9:1305–6.CrossRefPubMed Chin CY, Maehara A, Fall K, Mintz GS, Ali ZA. Imaging comparisons of coregistered native and stented coronary segments by high-definition 60-MHz intravascular ultrasound and optical coherence tomography. JACC Cardiovasc Interv. 2016;9:1305–6.CrossRefPubMed
28.
Zurück zum Zitat Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014;9:1271–84.CrossRefPubMed Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014;9:1271–84.CrossRefPubMed
29.
Zurück zum Zitat Brugaletta S, Garcia-Garcia HM, Garg S, Gomez-Lara J, Diletti R, Onuma Y, et al. Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. Int J Cardiovasc Imaging. 2011;27:859–66.CrossRefPubMed Brugaletta S, Garcia-Garcia HM, Garg S, Gomez-Lara J, Diletti R, Onuma Y, et al. Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. Int J Cardiovasc Imaging. 2011;27:859–66.CrossRefPubMed
30.
Zurück zum Zitat Campos CM, Ishibashi Y, Eggermont J, Nakatani S, Cho YK, Dijkstra J, et al. Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12–18, 24-, 30-, 36- and 42-month follow-up in a porcine model. Int J Cardiovasc Imaging. 2015;31:471–82.CrossRefPubMedPubMedCentral Campos CM, Ishibashi Y, Eggermont J, Nakatani S, Cho YK, Dijkstra J, et al. Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12–18, 24-, 30-, 36- and 42-month follow-up in a porcine model. Int J Cardiovasc Imaging. 2015;31:471–82.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Schaar JA, De Korte CL, Mastik F, Strijder C, Pasterkamp G, Boersma E, et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation. 2003;108:2636–41.CrossRefPubMed Schaar JA, De Korte CL, Mastik F, Strijder C, Pasterkamp G, Boersma E, et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation. 2003;108:2636–41.CrossRefPubMed
32.
Zurück zum Zitat Schaar JA, Regar E, Mastik F, McFadden EP, Saia F, Disco C, et al. Incidence of high-strain patterns in human coronary arteries: assessment with three-dimensional intravascular palpography and correlation with clinical presentation. Circulation. 2004;109:2716–9.CrossRefPubMed Schaar JA, Regar E, Mastik F, McFadden EP, Saia F, Disco C, et al. Incidence of high-strain patterns in human coronary arteries: assessment with three-dimensional intravascular palpography and correlation with clinical presentation. Circulation. 2004;109:2716–9.CrossRefPubMed
33.
Zurück zum Zitat Garcia-Garcia HM, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L, et al. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention. 2009;4:443–8.CrossRefPubMed Garcia-Garcia HM, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L, et al. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention. 2009;4:443–8.CrossRefPubMed
34.
Zurück zum Zitat Nakatani S, Sotomi Y, Ishibashi Y, Grundeken MJ, Tateishi H, Tenekecioglu E, et al. Comparative analysis method of permanent metallic stents (XIENCE) and bioresorbable poly-l-lactic (PLLA) scaffolds (Absorb) on optical coherence tomography at baseline and follow-up. EuroIntervention. 2016;12:1498–509.CrossRefPubMed Nakatani S, Sotomi Y, Ishibashi Y, Grundeken MJ, Tateishi H, Tenekecioglu E, et al. Comparative analysis method of permanent metallic stents (XIENCE) and bioresorbable poly-l-lactic (PLLA) scaffolds (Absorb) on optical coherence tomography at baseline and follow-up. EuroIntervention. 2016;12:1498–509.CrossRefPubMed
35.
Zurück zum Zitat Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen NS, Freire R, Dijkstra J, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2014;64:2343–56.CrossRefPubMed Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen NS, Freire R, Dijkstra J, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2014;64:2343–56.CrossRefPubMed
36.
Zurück zum Zitat van Soest G, Goderie T, Regar E, Koljenovic S, van Leenders GL, Gonzalo N, et al. Atherosclerotic tissue characterization in vivo by optical coherence tomography attenuation imaging. J Biomed Opt. 2010;15:011105.CrossRefPubMed van Soest G, Goderie T, Regar E, Koljenovic S, van Leenders GL, Gonzalo N, et al. Atherosclerotic tissue characterization in vivo by optical coherence tomography attenuation imaging. J Biomed Opt. 2010;15:011105.CrossRefPubMed
37.
Zurück zum Zitat Ughi GJ, Adriaenssens T, Sinnaeve P, Desmet W, D’Hooge J. Automated tissue characterization of in vivo atherosclerotic plaques by intravascular optical coherence tomography images. Biomed Opt Express. 2013;4:1014–30.CrossRefPubMedPubMedCentral Ughi GJ, Adriaenssens T, Sinnaeve P, Desmet W, D’Hooge J. Automated tissue characterization of in vivo atherosclerotic plaques by intravascular optical coherence tomography images. Biomed Opt Express. 2013;4:1014–30.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Methe H, Balcells M, Alegret Mdel C, Santacana M, Molins B, Hamik A, et al. Vascular bed origin dictates flow pattern regulation of endothelial adhesion molecule expression. Am J Physiol Heart Circ Physiol. 2007;292:H2167–75.CrossRefPubMed Methe H, Balcells M, Alegret Mdel C, Santacana M, Molins B, Hamik A, et al. Vascular bed origin dictates flow pattern regulation of endothelial adhesion molecule expression. Am J Physiol Heart Circ Physiol. 2007;292:H2167–75.CrossRefPubMed
39.
Zurück zum Zitat Bourantas CV, Papafaklis MI, Kotsia A, Farooq V, Muramatsu T, Gomez-Lara J, et al. Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography study. JACC Cardiovasc Interv. 2014;7:315–24.CrossRefPubMed Bourantas CV, Papafaklis MI, Kotsia A, Farooq V, Muramatsu T, Gomez-Lara J, et al. Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography study. JACC Cardiovasc Interv. 2014;7:315–24.CrossRefPubMed
40.
Zurück zum Zitat Sotomi Y, Tateishi H, Suwannasom P, Dijkstra J, Eggermont J, Liu S, et al. Quantitative assessment of the stent/scaffold strut embedment analysis by optical coherence tomography. Int J Cardiovasc Imaging. 2016;32:871–83.CrossRefPubMedPubMedCentral Sotomi Y, Tateishi H, Suwannasom P, Dijkstra J, Eggermont J, Liu S, et al. Quantitative assessment of the stent/scaffold strut embedment analysis by optical coherence tomography. Int J Cardiovasc Imaging. 2016;32:871–83.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. J Am Coll Cardiol. 2012;59:1337–49.CrossRefPubMed Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. J Am Coll Cardiol. 2012;59:1337–49.CrossRefPubMed
42.
Zurück zum Zitat Papafaklis MI, Bourantas CV, Farooq V, Diletti R, Muramatsu T, Zhang Y, et al. In vivo assessment of the three-dimensional haemodynamic micro-environment following drug-eluting bioresorbable vascular scaffold implantation in a human coronary artery: fusion of frequency domain optical coherence tomography and angiography. EuroIntervention. 2013;9:890.CrossRefPubMed Papafaklis MI, Bourantas CV, Farooq V, Diletti R, Muramatsu T, Zhang Y, et al. In vivo assessment of the three-dimensional haemodynamic micro-environment following drug-eluting bioresorbable vascular scaffold implantation in a human coronary artery: fusion of frequency domain optical coherence tomography and angiography. EuroIntervention. 2013;9:890.CrossRefPubMed
43.
Zurück zum Zitat Mejia J, Ruzzeh B, Mongrain R, Leask R, Bertrand OF. Evaluation of the effect of stent strut profile on shear stress distribution using statistical moments. Biomed Eng Online. 2009;8:8.CrossRefPubMedPubMedCentral Mejia J, Ruzzeh B, Mongrain R, Leask R, Bertrand OF. Evaluation of the effect of stent strut profile on shear stress distribution using statistical moments. Biomed Eng Online. 2009;8:8.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Sotomi Y, Onuma Y, Dijkstra J, Eggermont J, Liu S, Tenekecioglu E, et al. Impact of implantation technique and plaque morphology on strut embedment and scaffold expansion of polylactide bioresorbable scaffold-insights from ABSORB Japan Trial. Circ J. 2016;80:2317–26.CrossRefPubMed Sotomi Y, Onuma Y, Dijkstra J, Eggermont J, Liu S, Tenekecioglu E, et al. Impact of implantation technique and plaque morphology on strut embedment and scaffold expansion of polylactide bioresorbable scaffold-insights from ABSORB Japan Trial. Circ J. 2016;80:2317–26.CrossRefPubMed
45.
Zurück zum Zitat Sotomi Y, Onuma Y, Dijkstra J, et al. Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial. Eur Heart J Cardiovasc Imaging. 2017. doi:10.1093/ehjci/jew329.PubMed Sotomi Y, Onuma Y, Dijkstra J, et al. Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial. Eur Heart J Cardiovasc Imaging. 2017. doi:10.​1093/​ehjci/​jew329.PubMed
46.
Zurück zum Zitat Sotomi Y, Suwannasom P, Serruys PW, Onuma Y. Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. EuroIntervention. 2017;12:1747–56.CrossRefPubMed Sotomi Y, Suwannasom P, Serruys PW, Onuma Y. Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. EuroIntervention. 2017;12:1747–56.CrossRefPubMed
47.
Zurück zum Zitat Raber L, Brugaletta S, Yamaji K, O’Sullivan CJ, Otsuki S, Koppara T, et al. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol. 2015;66:1901–14.CrossRefPubMed Raber L, Brugaletta S, Yamaji K, O’Sullivan CJ, Otsuki S, Koppara T, et al. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol. 2015;66:1901–14.CrossRefPubMed
48.
Zurück zum Zitat Cuculi F, Puricel S, Jamshidi P, Valentin J, Kallinikou Z, Toggweiler S, et al. Optical coherence tomography findings in bioresorbable vascular scaffolds thrombosis. Circ Cardiovasc Interv. 2015;8:e002518.PubMed Cuculi F, Puricel S, Jamshidi P, Valentin J, Kallinikou Z, Toggweiler S, et al. Optical coherence tomography findings in bioresorbable vascular scaffolds thrombosis. Circ Cardiovasc Interv. 2015;8:e002518.PubMed
49.
Zurück zum Zitat Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7:330–42.CrossRefPubMed Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7:330–42.CrossRefPubMed
50.
Zurück zum Zitat Bourantas CV, Papafaklis MI, Lakkas L, Sakellarios A, Onuma Y, Zhang YJ, et al. Fusion of optical coherence tomographic and angiographic data for more accurate evaluation of the endothelial shear stress patterns and neointimal distribution after bioresorbable scaffold implantation: comparison with intravascular ultrasound-derived reconstructions. Int J Cardiovasc Imaging. 2014;30:485–94.CrossRefPubMed Bourantas CV, Papafaklis MI, Lakkas L, Sakellarios A, Onuma Y, Zhang YJ, et al. Fusion of optical coherence tomographic and angiographic data for more accurate evaluation of the endothelial shear stress patterns and neointimal distribution after bioresorbable scaffold implantation: comparison with intravascular ultrasound-derived reconstructions. Int J Cardiovasc Imaging. 2014;30:485–94.CrossRefPubMed
51.
Zurück zum Zitat Tenekecioglu E, Poon EK, Collet C, Thondapu V, Torii R, Bourantas CV, et al. The nidus for possible thrombus formation: insight from the microenvironment of bioresorbable vascular scaffold. JACC Cardiovasc Interv. 2016;9:2167–8.CrossRefPubMed Tenekecioglu E, Poon EK, Collet C, Thondapu V, Torii R, Bourantas CV, et al. The nidus for possible thrombus formation: insight from the microenvironment of bioresorbable vascular scaffold. JACC Cardiovasc Interv. 2016;9:2167–8.CrossRefPubMed
52.
Zurück zum Zitat Tenekecioglu E, Torii R, Bourantas C, Abdelghani M, Cavalcante R, Sotomi Y, et al. Assessment of the hemodynamic characteristics of absorb BVS in a porcine coronary artery model. Int J Cardiol. 2017;227:467–73.CrossRefPubMed Tenekecioglu E, Torii R, Bourantas C, Abdelghani M, Cavalcante R, Sotomi Y, et al. Assessment of the hemodynamic characteristics of absorb BVS in a porcine coronary artery model. Int J Cardiol. 2017;227:467–73.CrossRefPubMed
53.
Zurück zum Zitat Ueda Y, Matsuo K, Nishimoto Y, Sugihara R, Hirata A, Takeda Y, et al. The importance of intracoronary imaging when we speculate long-term outcome of new intracoronary stents. Angioscopy. 2015;1:17–20.CrossRef Ueda Y, Matsuo K, Nishimoto Y, Sugihara R, Hirata A, Takeda Y, et al. The importance of intracoronary imaging when we speculate long-term outcome of new intracoronary stents. Angioscopy. 2015;1:17–20.CrossRef
54.
Zurück zum Zitat Spuentrup E, Ruebben A, Mahnken A, Stuber M, Kolker C, Nguyen TH, et al. Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circulation. 2005;111:1019–26.CrossRefPubMed Spuentrup E, Ruebben A, Mahnken A, Stuber M, Kolker C, Nguyen TH, et al. Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circulation. 2005;111:1019–26.CrossRefPubMed
55.
Zurück zum Zitat Nieman K, Serruys PW, Onuma Y, van Geuns RJ, Garcia-Garcia HM, de Bruyne B, et al. Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). J Am Coll Cardiol. 2013;62:1813–4.CrossRefPubMed Nieman K, Serruys PW, Onuma Y, van Geuns RJ, Garcia-Garcia HM, de Bruyne B, et al. Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). J Am Coll Cardiol. 2013;62:1813–4.CrossRefPubMed
56.
Zurück zum Zitat Collet C, Sotomi Y, Cavalcante R, Asano T, Miyazaki Y, Tenekecioglu E, et al. Accuracy of coronary computed tomography angiography for bioresorbable scaffold luminal investigation: a comparison with optical coherence tomography. Int J Cardiovasc Imaging. 2017;33:431–9.CrossRefPubMed Collet C, Sotomi Y, Cavalcante R, Asano T, Miyazaki Y, Tenekecioglu E, et al. Accuracy of coronary computed tomography angiography for bioresorbable scaffold luminal investigation: a comparison with optical coherence tomography. Int J Cardiovasc Imaging. 2017;33:431–9.CrossRefPubMed
57.
Zurück zum Zitat Onuma Y, Collet C, van Geuns RJ, et al. Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy. Eur Heart J Cardiovasc Imaging. 2017. doi:10.1093/ehjci/jex022. Onuma Y, Collet C, van Geuns RJ, et al. Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy. Eur Heart J Cardiovasc Imaging. 2017. doi:10.​1093/​ehjci/​jex022.
58.
Zurück zum Zitat Barone-Rochette G, Vautrin E, Rodiere M, Broisat A, Vanzetto G. First magnetic resonance coronary artery imaging of bioresorbable vascular scaffold in-patient. Eur Heart J Cardiovasc Imaging. 2015;16:229.CrossRefPubMed Barone-Rochette G, Vautrin E, Rodiere M, Broisat A, Vanzetto G. First magnetic resonance coronary artery imaging of bioresorbable vascular scaffold in-patient. Eur Heart J Cardiovasc Imaging. 2015;16:229.CrossRefPubMed
59.
60.
Zurück zum Zitat Abizaid A. Desolve Nx, Cx and amity: unique properties and results from 150 µm to 120 µm. In: Presented at TCT 2016. Abizaid A. Desolve Nx, Cx and amity: unique properties and results from 150 µm to 120 µm. In: Presented at TCT 2016.
61.
Zurück zum Zitat Abizaid A. FANTOM II: six-month and nine-month clinical and angiographic results with a radiopaque desaminotyrosine polycarbonate-based sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease. In: Presented at TCT 2016. Abizaid A. FANTOM II: six-month and nine-month clinical and angiographic results with a radiopaque desaminotyrosine polycarbonate-based sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease. In: Presented at TCT 2016.
62.
Zurück zum Zitat Seth A. MeRes100—design specifications and the 6-months MeRes-1 results. In: Presented at TCT 2016. Seth A. MeRes100—design specifications and the 6-months MeRes-1 results. In: Presented at TCT 2016.
63.
Zurück zum Zitat Colombo A. FORTITUDE: Nine-month clinical, angiographic, and OCT results with an amorphous PLLA-based sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease. In: Presented at TCT 2016. Colombo A. FORTITUDE: Nine-month clinical, angiographic, and OCT results with an amorphous PLLA-based sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease. In: Presented at TCT 2016.
64.
Zurück zum Zitat Xu B. FIRESORB PLLA-based sirolimus-eluting scaffold: 6-month FUTURE-I Results. In: Presented at TCT 2016. Xu B. FIRESORB PLLA-based sirolimus-eluting scaffold: 6-month FUTURE-I Results. In: Presented at TCT 2016.
65.
Zurück zum Zitat Geuns R-Jv. Highlights (and my interpretations) from: new BRS—FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6–9 month results). In: Presented at TCT 2016. Geuns R-Jv. Highlights (and my interpretations) from: new BRS—FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6–9 month results). In: Presented at TCT 2016.
66.
Zurück zum Zitat Serruys PW, Onuma Y. Dmax for sizing, PSP-1, PSP-2, PSP-3 or OCT guidance: interventionalist’s jargon or indispensable implantation techniques for short- and long-term outcomes of Absorb BRS? EuroIntervention. 2017;12:2047–56.CrossRefPubMed Serruys PW, Onuma Y. Dmax for sizing, PSP-1, PSP-2, PSP-3 or OCT guidance: interventionalist’s jargon or indispensable implantation techniques for short- and long-term outcomes of Absorb BRS? EuroIntervention. 2017;12:2047–56.CrossRefPubMed
67.
Zurück zum Zitat Ortega-Paz L, Capodanno D, Gori T, Nef H, Latib A, Caramanno G, et al. Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention. 2017;12:2110–7.CrossRefPubMed Ortega-Paz L, Capodanno D, Gori T, Nef H, Latib A, Caramanno G, et al. Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention. 2017;12:2110–7.CrossRefPubMed
68.
Zurück zum Zitat Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67:921–31.CrossRefPubMed Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67:921–31.CrossRefPubMed
69.
Zurück zum Zitat Shimamura K, Guagliumi G. Optical coherence tomography for online guidance of complex coronary interventions. Circ J. 2016;80:2063–72.CrossRefPubMed Shimamura K, Guagliumi G. Optical coherence tomography for online guidance of complex coronary interventions. Circ J. 2016;80:2063–72.CrossRefPubMed
70.
Zurück zum Zitat Alberts B. Molecular biology of the cell. 4th ed. New York: Garland Science; 2002. Alberts B. Molecular biology of the cell. 4th ed. New York: Garland Science; 2002.
Metadaten
Titel
Imaging assessment of bioresorbable vascular scaffolds
verfasst von
Yohei Sotomi
Pannipa Suwannasom
Erhan Tenekecioglu
Carlos Collet
Shimpei Nakatani
Takayuki Okamura
Takashi Muramatsu
Yuki Ishibashi
Hiroki Tateishi
Yosuke Miyazaki
Taku Asano
Yuki Katagiri
Constantin von zur Muehlen
Kengo Tanabe
Ken Kozuma
Yukio Ozaki
Patrick W. Serruys
Yoshinobu Onuma
Publikationsdatum
01.08.2017
Verlag
Springer Japan
Erschienen in
Cardiovascular Intervention and Therapeutics / Ausgabe 1/2018
Print ISSN: 1868-4300
Elektronische ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-017-0486-5

Weitere Artikel der Ausgabe 1/2018

Cardiovascular Intervention and Therapeutics 1/2018 Zur Ausgabe

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.